文献速递重症综合管理与镇静镇痛心脑血管急症

基于电子健康记录数据的神经重症监护绩效指标可行且揭示机构间差异:CHoRUS试点项目

Neurocritical Care Performance Measures Derived from Electronic Health Record Data are Feasible and Reveal Site-Specific Variation: A CHoRUS Pilot Project.
PubMed 文献 · Neurocrit Care · 2022-06-10
一句话结论在三个中心14985例神经重症监护住院患者中,从电子健康记录提取的5项神经重症绩效指标可行且存在机构间差异,但延迟间歇充气加压装置与静脉血栓栓塞的关联仅在中心3达到统计学显著。

该研究在CHoRUS联盟三个中心纳入2015年3月至2020年2月连续神经重症监护住院超过24小时的患者,评估从电子健康记录流程表数据提取的5项临床绩效指标与质量指标的可行性、区分度及机构间差异。共14985例纳入,颅内压监测记录于1514例(10.1%),神经系统评估记录于14635例(91.1%),间歇充气加压装置应用记录于14175例(88.5%)。颅内压监测启动延迟、护士记录的神经系统评估频率及院内静脉血栓栓塞发生率均存在机构间差异(p < 0.001)。延迟间歇充气加压装置启动与静脉血栓栓塞的关联仅在中心3达到统计学显著(p = 0.036)。作者认为电子健康记录来源的神经重症绩效指标报告可行并显示机构间差异,未来应研究绩效或记录行为驱动这些指标、相关结局及指标是否可干预。

要点

  • 三个中心共14985例神经重症监护住院超过24小时患者中,颅内压监测记录于1514例(10.1%),其中1267例(83.7%)在24小时内启动。
  • 颅内压监测启动延迟存在机构间差异:中心1为0.54小时(四分位距2.82),中心2为0.58小时(1.68),中心3为2.36小时(4.60),p < 0.001。
  • 护士记录的神经系统评估频率机构间差异显著:中心1为17.4次/天(5.97),中心2为8.4次/天(3.12),中心3为15.3次/天(8.34),p < 0.001;日间6.90次/天 vs 夜间5.67次/天,p < 0.001。
  • 符合临床 eligibility 的患者中,12863例(90.7%)在24小时内应用间歇充气加压装置;院内静脉血栓栓塞发生率机构间差异显著(1.23%、1.55%、5.18%,p < 0.001)。
  • 延迟间歇充气加压装置启动与静脉血栓栓塞的关联仅在中心3达到统计学显著(0.40小时[16.3] vs 0.35小时[11.5],p = 0.036),总体(p = 0.479)、中心1(p = 0.713)、中心2(p = 0.216)均未达统计学显著。

适用人群与场景

  • 三个中心(CHoRUS联盟)连续神经重症监护住院超过24小时的患者,时间范围2015年3月至2020年2月。
  • 评估间歇充气加压装置应用时,排除电子健康记录中记录有限制性损伤、正在行走或拒绝预防的患者。

诊断标准与关键阈值

  • 间歇充气加压装置临床 eligibility:排除电子健康记录中记录有限制性损伤、正在行走或拒绝预防的患者。

研究设计与关键结果

  • 研究类型:CHoRUS试点项目,在三个中心评估电子健康记录提取的绩效指标可行性、区分度及机构间差异。
  • 样本量:14985例神经重症监护住院超过24小时患者。
  • 颅内压监测记录于1514例(10.1%),其中1267例(83.7%)在24小时内启动;启动延迟机构间差异:中心1 0.54小时(四分位距2.82)、中心2 0.58小时(1.68)、中心3 2.36小时(4.60),p < 0.001。
  • 神经系统评估记录于14635例(91.1%);护士记录的评估频率机构间差异:中心1 17.4次/天(5.97)、中心2 8.4次/天(3.12)、中心3 15.3次/天(8.34),p < 0.001;日间6.90次/天 vs 夜间5.67次/天,p < 0.001。
  • 间歇充气加压装置应用记录于14175例(88.5%);符合临床 eligibility 的患者中12863例(90.7%)在24小时内应用。
  • 院内静脉血栓栓塞发生率机构间差异:中心1 1.23%、中心2 1.55%、中心3 5.18%,p < 0.001。
  • 延迟间歇充气加压装置启动与静脉血栓栓塞的关联:总体1.02小时(10.4)vs 0.97小时(5.98),p = 0.479;中心1 2.25小时(10.27)vs 1.82小时(7.39),p = 0.713;中心2 1.38小时(5.90)vs 0.80小时(0.53),p = 0.216;中心3 0.40小时(16.3)vs 0.35小时(11.5),p = 0.036。

证据类型、等级与局限

  • 证据类型:CHoRUS试点项目,多中心评估电子健康记录提取绩效指标的可行性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为电子健康记录来源的神经重症绩效指标报告可行并显示机构间差异。
  • 作者认为未来应研究绩效或记录行为驱动这些指标、与绩效相关的结局,以及电子健康记录来源的绩效指标和质量指标是否可干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We evaluated the feasibility and discriminability of recently proposed Clinical Performance Measures for Neurocritical Care (Neurocritical Care Society) and Quality Indicators for Traumatic Brain Injury (Collaborative European NeuroTrauma Effectiveness Research in TBI; CENTER-TBI) extracted from electronic health record (EHR) flowsheet data.

METHODS: At three centers within the Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI consortium, we examined consecutive neurocritical care admissions exceeding 24 h (03/2015-02/2020) and evaluated the feasibility, discriminability, and site-specific variation of five clinical performance measures and quality indicators: (1) intracranial pressure (ICP) monitoring (ICPM) within 24 h when indicated, (2) ICPM latency when initiated within 24 h, (3) frequency of nurse-documented neurologic assessments, (4) intermittent pneumatic compression device (IPCd) initiation within 24 h, and (5) latency to IPCd application. We additionally explored associations between delayed IPCd initiation and codes for venous thromboembolism documented using the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) system. Median (interquartile range) statistics are reported. Kruskal-Wallis tests were measured for differences across centers, and Dunn statistics were reported for between-center differences.

RESULTS: A total of 14,985 admissions met inclusion criteria. ICPM was documented in 1514 (10.1%), neurologic assessments in 14,635 (91.1%), and IPCd application in 14,175 (88.5%). ICPM began within 24 h for 1267 (83.7%), with site-specific latency differences among sites 1-3, respectively, (0.54 h [2.82], 0.58 h [1.68], and 2.36 h [4.60]; p < 0.001). The frequency of nurse-documented neurologic assessments also varied by site (17.4 per day [5.97], 8.4 per day [3.12], and 15.3 per day [8.34]; p < 0.001) and diurnally (6.90 per day during daytime hours vs. 5.67 per day at night, p < 0.001). IPCds were applied within 24 h for 12,863 (90.7%) patients meeting clinical eligibility (excluding those with EHR documentation of limiting injuries, actively documented as ambulating, or refusing prophylaxis). In-hospital venous thromboembolism varied by site (1.23%, 1.55%, and 5.18%; p < 0.001) and was associated with increased IPCd latency (overall, 1.02 h [10.4] vs. 0.97 h [5.98], p = 0.479; site 1, 2.25 h [10.27] vs. 1.82 h [7.39], p = 0.713; site 2, 1.38 h [5.90] vs. 0.80 h [0.53], p = 0.216; site 3, 0.40 h [16.3] vs. 0.35 h [11.5], p = 0.036).

CONCLUSIONS: Electronic health record-derived reporting of neurocritical care performance measures is feasible and demonstrates site-specific variation. Future efforts should examine whether performance or documentation drives these measures, what outcomes are associated with performance, and whether EHR-derived measures of performance measures and quality indicators are modifiable.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Ack SE, Loiseau SY, Sharma G, et al. Neurocritical Care Performance Measures Derived from Electronic Health Record Data are Feasible and Reveal Site-Specific Variation: A CHoRUS Pilot Project. Neurocrit Care. 2022. PMID: 35689135. doi:10.1007/s12028-022-01497-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。